Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology
- 1 March 2012
- journal article
- Published by Wiley in European Journal of Heart Failure
- Vol. 14 (3), 268-277
- https://doi.org/10.1093/eurjhf/hfs006
Abstract
In patients with ischaemic heart failure (HF), myocardial dysfunction often progresses. Elevated levels of soluble ST2 (sST2) are associated with a poor prognosis, but an association between sST2 and worsening heart failure per se has not been established. We assessed the association between sST2 and cause-specific outcome in 1449 patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA study). Soluble ST2 was measured with a highly sensitive immunoassay in 1449 patients ≥60 years of age with left ventricular ejection fraction (LVEF) ≤40% due to ischaemic heart disease. By Cox regression analyses, we found sST2 to be associated with the primary endpoint, i.e. a composite of cadiovascular (CV) death, non-fatal myocardial infarction, or stroke, as well as all pre-defined secondary endpoints in the CORONA study, even after adjustment for baseline clinical variables. After adjustment for N-terminal pro brain natriuretic peptide and C-reactive protein, the association between sST2 and the primary endpoint was attenuated and no longer statistically significant. However, sST2 remained associated with death due to worsening HF, hospitalization due to worsening HF, and hospitalization due to any CV cause, even after full adjustment. Soluble ST2 is associated with adverse outcomes in older patients with systolic, ischaemic HF. In particular, sST2 is independently associated with worsening HF.This publication has 30 references indexed in Scilit:
- The Aging Heart and Post-Infarction Left Ventricular RemodelingJournal of the American College of Cardiology, 2011
- Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute DyspneaCirculation: Heart Failure, 2009
- Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial InfarctionCirculation, 2008
- Epidemiology and risk stratification in acute heart failureAmerican Heart Journal, 2008
- Measurement of the Interleukin Family Member ST2 in Patients With Acute DyspneaJournal of the American College of Cardiology, 2007
- Inflammatory Biomarkers in Heart FailureCongestive Heart Failure, 2006
- Systemic inflammation in heart failure – The whys and whereforesHeart Failure Reviews, 2006
- IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated CytokinesImmunity, 2005
- Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial InfarctionCirculation, 2004
- Postinfarction left ventricular remodelling: where are the theories and trials leading us?Heart, 2000